UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of July 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On July 13, 2026, Ascentage Pharma Group International issued the announcement: “Update on The Further Grant Of Awards Under The 2021 RSU Scheme And The 2022 RSU Scheme; And Further Grant Of Options Under The Post IPO Share Option Scheme”. A copy of the announcement is furnished as Exhibit 99.1.

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title

99.1		Announcement dated July 13, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL

Date: July 13, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

ASCENTAGE PHARMA GROUP INTERNATIONAL 6-K